Press Release

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

09/02/21

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences:

  • Kevin Gorman, Chief Executive Officer, will present at the Morgan Stanley 19th Annual Healthcare Conference at 10:15 a.m. ET on Monday, Sept. 13, 2021.
  • Matt Abernethy, Chief Financial Officer, and Eiry Roberts, Chief Medical Officer, will present at the Baird 2021 Global Healthcare Conference at 10:50 a.m. ET on Wednesday, Sept. 15, 2021.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn(*in collaboration with AbbVie)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301368799.html

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc., Tony Jewell (Media), 858-617-7578, media@neurocrine.com, or Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com